阿斯利康新冠肺炎疫苗在老年人中前景看好,圣诞节前试验结果

2020-11-19 18:08

AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas oRi世界播

阿斯利康新冠肺炎疫苗在老年人中前景看好,圣诞节前试验结果oRi世界播


LONDON (Reuters) - AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas. oRi世界播

伦敦(路透社)-周四公布的数据显示,阿斯利康和牛津大学潜在的新冠肺炎疫苗在老年人中产生了强烈的免疫反应,研究人员预计将在圣诞节前公布后期试验结果。oRi世界播


The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70, who are at higher risk of serious illness and death from COVID-19, could build robust immunity. oRi世界播

上个月报道了部分数据,但周四全文发表在医学期刊《柳叶刀》(Lancet)上。这些数据表明,70岁以上的人患重病和死于新冠肺炎的风险更高,他们可以建立强大的免疫力。oRi世界播


"The robust antibody and T-cell responses seen in older people in our study are encouraging," said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group. oRi世界播

牛津疫苗集团顾问兼联合首席研究员马赫希·拉马萨米(Mahehi Ramasamy)说:“在我们的研究中,在老年人身上看到的强大抗体和T细胞反应令人鼓舞。”oRi世界播


"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure." oRi世界播

“我们希望这意味着我们的疫苗将有助于保护社会上一些最脆弱的人群,但在我们确定之前,还需要进一步的研究。”oRi世界播


Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions. oRi世界播

研究人员说,后期或第三阶段的试验正在进行中,以证实这一发现,并测试疫苗是否能在广泛的人群中预防感染SARS-CoV-2,包括有潜在健康状况的人。oRi世界播


Results of those trials should definitely be known by Christmas, the Oxford Vaccine Group's director Andrew Pollard said, adding it was too early to know whether and how well the vaccine works in preventing COVID-19 disease. oRi世界播

牛津疫苗集团主任安德鲁·波拉德表示,这些试验的结果肯定会在圣诞节前公布,并补充说,现在就知道疫苗在预防新冠肺炎病方面是否有效以及效果如何还为时过早。oRi世界播


"We haven't quite got to that point yet. We're obviously not going to rush that," he told BBC radio. "We're getting close, and it's definitely going to be before Christmas, based on the progress." [nL9N2G0025] oRi世界播

他告诉BBC电台:“我们还没有到那个地步。我们显然不会仓促行事。”“我们已经很接近了,根据进展情况,我们肯定会在圣诞节前完成这项工作。”[nL9N2G0025]。oRi世界播


The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2. oRi世界播

牛津-阿斯利康新冠肺炎候选疫苗,名为AZD1222或ChAdOx1nCoV-19,在开发疫苗以预防感染新型冠状病毒(SARS-CoV-2)的全球努力中一直处于领先地位。oRi世界播


But rival drugmakers Pfizer Inc , BioNTech and Moderna Inc have in the past 10 days edged ahead, releasing data from late-stage COVID-19 vaccine trials that shows more than 90% efficacy. oRi世界播

但竞争对手辉瑞公司(Pfizer Inc.)、生物技术公司(BioNTech)和现代公司(Modern na Inc.)在过去10天里略微领先,发布了晚期新冠肺炎疫苗试验的数据,显示出90%以上的疗效。oRi世界播


Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca's is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees. oRi世界播

与辉瑞生物科技和现代疫苗不同的是,这两种疫苗都使用了信使RNA(MRNA)新技术,而阿斯利康的疫苗是一种病毒载体疫苗,由在黑猩猩身上发现的普通感冒病毒的弱化版本制成。oRi世界播


The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55 years, 160 aged 56-69 years, and 240 aged 70 or over. oRi世界播

柳叶刀上报道的第二阶段试验共涉及560名健康志愿者,其中160名年龄在18-55岁,160名年龄在56-69岁,240名年龄在70岁或以上。oRi世界播


Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said. oRi世界播

研究人员说,志愿者接种了两剂疫苗或安慰剂,没有与AZD1222疫苗相关的严重副作用报告。oRi世界播


AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world. oRi世界播

阿斯利康已经与世界各地的公司和政府签署了几项供应和制造协议。oRi世界播

© 2016 世界播 www.shijiebobao.com 中国互联网举报中心 京ICP证140141号 鄂ICP备18018000号-1
违法和不良信息举报: